Industry Insights Seminar Series: Accelerating COVID-19 antibody discovery through industry-academia consortium
Tuesday, 06 April 2021, 12pm to 1.30pm
Dr Jane Osbourn OBE, CSO of Alchemab and Professor Paul Kellam, VP Infectious diseases and vaccines at Kymab, will discuss their collaborative roles in the BioIndustry Association's Antibody Taskforce to identify and develop new therapeutics in the fight against COVID-19.
The BIA Antibody Taskforce is a world-leading consortium of biotech companies, charities and academia experts based across the UK who share a joint commitment to help fight the COVID-19 pandemic. Contributing their expertise and specialist resources, the team is working together to rapidly identify the most promising antibodies with the potential to positively impact the treatment of those affected by this devastating virus.
The goal of the Taskforce is to develop an antibody-based treatment for patients with COVID-19, which could also potentially work as a preventative therapy for high-risk individuals and complement the current vaccination strategy. As part of a global hub for the life sciences, the UK BIA Antibody Taskforce wants to truly make a difference to people's lives.
For more information on the BIA Antibody Taskforce, click here.